Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of stem cell therapies for degenerative diseases and immunotherapies for cancer utilizing proprietary cell therapy technologies. The Company is the result of the acquisition, transfer and advancement of over thirty years of research and human treatment experience in cellular medicine. CBMG’s cellular research and development comes from a collaboration among scientists and doctors from the US, Europe and China. SNNLive spoke with Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group, Inc. at Healthcare Media Day 2015 in San Francisco, CA.
Dr. Cao begins the interview with an overview of the company, in particular focusing on how CBMG is developing stem cell and immune cell therapies to treat degenerative and cancerous diseases. He also discusses the Company’s Phase II clinical trial for Knee Osteoarthritis (KOA), as well as highlighting CBMG’s IP portfolio, near-term milestones for 2015 and outlook for 2016. For more information about Cellular Biomedicine Group, Inc., please visit: www.CellBioMedGroup.com
© 2017 Stock News Now
Supported by Superior Web Solutions